How OncoResponse mines B cells of exceptional responders for antibodies, targets
OncoResponse Inc. is repurposing Theraclone Sciences Inc.'s I-STAR discovery platform to identify antibodies produced by exceptional responders to cancer immunotherapy. By tapping patients' natural immune responses, OncoResponse hopes to find novel immune targets and anticancer antibodies that can be engineered into antibody-drug conjugates or bispecific antibodies.
Theraclone and the University of Texas MD Anderson Cancer Center jointly launched OncoResponse last year. The newco holds exclusive, worldwide rights to the I-STAR platform to discover oncology candidates.
CEO Clifford Stocks told BioCentury, "As immuno-oncology became